Byung Hwa Jung has her expertise in metabolomics and DMPK (drug metabolism and pharmacokinetics). She has developed analytical methods for the quantitative and qualitative determination of endogenous metabolites and xenobiotics (drugs). The platforms for the non-targeted metabolomics and lipidomics using LC-MS for the evaluation of metabolic change in in vivo and in vitro systems were already established in her lab. Along with these systems, the quantitative analytical platforms for more than 170 metabolites and several drugs were also set up. The mechanisms and biomarkers for disease generation and development, and drug effect and adverse effects are studied with those systems.
